Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Cash & Equivalents: 2009-2025

Historic Revenue - Interest and Investment Income for Amicus Therapeutics (FOLD) over the last 1 years, with Mar 2011 value amounting to $102.6 million.

  • Amicus Therapeutics' Cash & Equivalents fell 18.42% to $190.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $190.6 million, marking a year-over-year decrease of 18.42%. This contributed to the annual value of $213.8 million for FY2024, which is 13.46% down from last year.
  • Latest data reveals that Amicus Therapeutics reported Cash & Equivalents of $190.6 million as of Q3 2025, which was up 20.10% from $158.7 million recorded in Q2 2025.
  • Amicus Therapeutics' 5-year Cash & Equivalents high stood at $385.9 million for Q3 2021, and its period low was $148.8 million during Q4 2022.
  • Moreover, its 3-year median value for Cash & Equivalents was $209.8 million (2024), whereas its average is $207.2 million.
  • Data for Amicus Therapeutics' Revenue - Interest and Investment Income shows a peak YoY surged of 31.84% (in 2010) over the last 5 years.
  • Over the past 3 years, Amicus Therapeutics' Revenue - Interest and Investment Income (Quarterly) stood at $85.4 million in 2009, then soared by 31.84% to $112.6 million in 2010, then reached $102.6 million in 2011.
  • Its last three reported values are $190.6 million in Q3 2025, $158.7 million for Q2 2025, and $181.7 million during Q1 2025.